MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Accueil・Liste d'Actions・Talphera Inc.

Talphera Inc.

Fermé

1.11 4.72

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.02

Max

1.12

Chiffres clés
By Trading Economics
Employés	13

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+200.93% upside

Dividendes
By Dow Jones
Prochains Résultats	30 mars 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-19M 42M
Ouverture précédente	-3.61
Clôture précédente	1.11

Talphera Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 déc. 2025, 22:20 UTC

Principaux Mouvements du Marché

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 déc. 2025, 17:31 UTC

Principaux Mouvements du Marché

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 déc. 2025, 16:30 UTC

Principaux Mouvements du Marché

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 déc. 2025, 15:19 UTC

Principaux Mouvements du Marché

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 déc. 2025, 15:17 UTC

Principaux Mouvements du Marché

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 déc. 2025, 14:37 UTC

Principaux Mouvements du Marché

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 déc. 2025, 21:13 UTC

Acquisitions, Fusions, Rachats

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 déc. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 déc. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 déc. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 déc. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 déc. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 déc. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 déc. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 déc. 2025, 17:16 UTC

Principaux Mouvements du Marché

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 déc. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 déc. 2025, 17:00 UTC

Acquisitions, Fusions, Rachats

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 déc. 2025, 15:57 UTC

Acquisitions, Fusions, Rachats

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 déc. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 déc. 2025, 15:02 UTC

Principaux Mouvements du Marché

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 déc. 2025, 14:40 UTC

Acquisitions, Fusions, Rachats

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 déc. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 déc. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 déc. 2025, 13:01 UTC

Résultats

Acquisitions, Fusions, Rachats

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 déc. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 déc. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31 déc. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 déc. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 déc. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Comparaison

Variation de prix

Talphera Inc. prévision

Objectif de Prix

By TipRanks

200.93% hausse

Prévisions sur 12 Mois

Moyen 3.25 USD 200.93%

Haut 3.5 USD

Bas 3 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

À Propos Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.